专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3244213A1 METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE 审中-公开
标题翻译：肾损伤和肾功能衰竭的诊断和预后的方法和组合物
公开(公告)号：EP3244213A1
公开(公告)日：2017-11-15
申请号：EP17171702.8
申请日：2010-02-05
申请人： Astute Medical, Inc.
发明人： ANDERBERG, Joseph , GRAY, Jeff , MCPHERSON, Paul , NAKAMURA, Kevin
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/50 , G01N2800/347 , G01N2800/56
摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Fibroblast growth factor 23, and optionally further one or more markers selected from the group consisting of soluble Advanced glycosylation end product-specific receptor, Bactericidal permeability-increasing protein, Interleukin 12, Vitamin K-dependent protein C, and Intestinal fatty acid-binding protein as diagnostic and prognostic biomarkers in renal injuries.
摘要翻译：本发明涉及用于监测，诊断，预后和确定患有或怀疑患有肾损伤的受试者的治疗方案的方法和组合物。具体而言，本发明涉及使用检测成纤维细胞生长因子23和任选地进一步选自可溶性高级糖基化终产物特异性受体，杀菌渗透性增加蛋白，白细胞介素12，维生素K- 依赖蛋白C和肠脂肪酸结合蛋白作为肾损伤诊断和预后生物标志物。

2. 发明授权

EP2613146B1 METHOD FOR MEASURING FIBROBLAST GROWTH FACTOR-23 AND REAGENT THEREFOR 有权
标题翻译：测量成纤维细胞生长因子-23的方法和试剂
公开(公告)号：EP2613146B1
公开(公告)日：2017-06-28
申请号：EP11821852.8
申请日：2011-08-31
申请人： KYOWA MEDEX CO., LTD.
发明人： UZAWA, Koji , SUZUKI, Emiko , IKEDA, Kazuyuki , MORITA, Kazuki
IPC分类号： G01N33/543 , G01N33/74
CPC分类号： G01N33/74 , G01N33/54326 , G01N2333/50

3. 发明公开

EP3047035A1 BIOMARKERS FOR TUBERCULOSIS 有权转让
标题翻译： BIOMARKERFÜRTUBERKULOSE
公开(公告)号：EP3047035A1
公开(公告)日：2016-07-27
申请号：EP14781260.6
申请日：2014-09-17
申请人： Medical Research Council
发明人： SUTHERLAND, Jayne
IPC分类号： C12Q1/68 , G01N33/50
CPC分类号： G01N33/6893 , A61K45/06 , C12Q1/6883 , G01N33/5695 , G01N33/6863 , G01N2333/485 , G01N2333/50 , G01N2333/5428 , G01N2333/5437 , G01N2333/5443 , G01N2333/545 , G01N2333/57 , G01N2800/26
摘要： In one aspect, provided herein is a method for detecting tuberculosis in a subject, comprising (a) determining a level of one or more host immune system biomarkers in a sputum sample obtained from the subject; and (b) comparing the levels of the biomarkers in the sputum sample to one or more reference values; wherein the levels of the biomarkers in the sputum sample compared to the reference values are indicative of the presence or absence of tuberculosis in the subject.
摘要翻译：一方面，本文提供了一种用于检测受试者中的结核病的方法，其包括（a）确定从受试者获得的痰样品中的一种或多种宿主免疫系统生物标志物的水平; 和（b）将痰样品中的生物标志物的水平与一个或多个参考值进行比较; 其中与参考值相比，痰样品中的生物标志物的水平指示受试者中存在或不存在结核病。

4. 发明授权

EP2138158B1 HAIR GROWTH-INHIBITING AGENT 有权
标题翻译： MEANS减少头发的生长
公开(公告)号：EP2138158B1
公开(公告)日：2015-09-30
申请号：EP08720753.6
申请日：2008-02-19
申请人： National Institute of Advanced Industrial Science and Technology
发明人： Imamura, Toru , Kimura, Miho , Kawano, Mitsuko , Tsujino, Nozomi , Kuramochi, Akiko , Oda, Yuko , Motomura, Kaori , Suzuki, Masashi , Asada, Masahiro , Kameyama, Azusa , Togayachi, Sumie , Oka, Syuichi
IPC分类号： A61K8/64 , A61K8/84 , A61K8/97 , A61Q9/04 , C07K14/435 , C12N15/09 , C12Q1/02 , C12Q1/68
CPC分类号： C07K14/43536 , A61K8/64 , A61Q7/02 , G01N33/566 , G01N2333/50 , G01N2500/10

5. 发明公开

EP2824181A4 NOVEL FGFR3 FUSION PRODUCT 有权
标题翻译：新型FGFR3融合产品
公开(公告)号：EP2824181A4
公开(公告)日：2015-07-15
申请号：EP13757006
申请日：2013-03-07
申请人： ASTELLAS PHARMA INC
发明人： SUZUKI ATSUSHI , ASAUMI MAKOTO , TSUNOYAMA KAZUHISA , NISHIMURA KOUICHI , MORINAKA AKIFUMI , YAMAUCHI TOMOHIRO , YOSHINO MASAYASU , YOSHIZAKI HIROAKI
IPC分类号： C12N15/09 , A61K45/00 , A61P35/00 , C12Q1/68 , G01N33/53
CPC分类号： A61K31/506 , A61K31/4439 , A61K31/496 , C07K14/47 , C07K14/71 , C07K2319/00 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , G01N33/57407 , G01N33/57423 , G01N33/74 , G01N2333/50
摘要： [Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. [Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.

6. 发明公开

EP2885429A1 DIAGNOSTIC MARKERS OF INDOLENT PROSTATE CANCER 失效
标题翻译：诊断标记物前列腺癌好逸恶劳
公开(公告)号：EP2885429A1
公开(公告)日：2015-06-24
申请号：EP13829362.6
申请日：2013-08-16
申请人： The Trustees of Columbia University in the City of New York
发明人： ABATE-SHEN, Corrine , SHEN, Michael , CALIFANO, Andrea , KANTH, Shazia, Irshad , BANSAL, Mukesh
IPC分类号： C12Q1/68 , G01N33/00
CPC分类号： G01N33/57434 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57415 , G01N33/57423 , G01N2333/4739 , G01N2333/50 , G01N2333/705 , G01N2333/71
摘要： A 3-gene prognostic panel has been identified that together accurately predicted the outcome of low Gleason score prostate tumors as either truly indolent or at a high risk of becoming aggressive. The 3-gene prognostic panel was validated on independent cohorts confirmed its independent prognostic value, as well as its ability to improve prognosis with currently used clinical nomograms. Expression of the 3-gene prognostic panel was determined by quantifying mRNA or protein encoded by the panel (collectively referred to as "prognostic biomarkers"). The prognostic biomarkers were discovered to be up-regulated in indolent tumors and down-regulated in aggressive forms of prostate cancer.

7. 发明公开

EP2617284A4 MODEL ANIMAL FOR STUDYING HAIR GROWTH CYCLE 有权
标题翻译：动物模型对头发的生长周期的研究
公开(公告)号：EP2617284A4
公开(公告)日：2014-04-30
申请号：EP11825257
申请日：2011-09-16
申请人： NAT INST OF ADVANCED IND SCIEN
发明人： IMAMURA TORU , UEKI MIHO , ODA YUKO
IPC分类号： A01K67/027 , C12N15/09 , G01N33/50
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/03 , G01N33/5088 , G01N2333/50

8. 发明公开

EP2707718A1 METHOD OF IDENTIFYING COMPOUNDS THAT SPECIFICALLY MODULATE THE INTERACTION OF FGFR1 AND BETA-KLOTHO 审中-公开
标题翻译：方法FGFR1和BETA KLOTHO的相互作用中识别化合物作为特异性调节
公开(公告)号：EP2707718A1
公开(公告)日：2014-03-19
申请号：EP12706412.9
申请日：2012-02-20
申请人： Amgen Inc.
发明人： LI, Yang , WU, Xinle , GE, Hongfei , BARIBAULT, Helene , LEMON, Bryan , SHENG, Jackie Zeqi , VONDERFECHT, Steven , WEISZMANN, Jennifer Veronica , GARDNER, Jonitha , LEE, Ki Jeong
IPC分类号： G01N33/566 , G01N33/74 , G01N33/50
CPC分类号： G01N33/74 , G01N33/5041 , G01N33/5044 , G01N33/5067 , G01N2333/50 , G01N2500/02
摘要： Methods of identifying compounds that specifically modulate the interaction of FGFR1 and β-Klotho are disclosed. Identified compounds can be useful in treating metabolic diseases and disorders that involve the interaction of FGFR1 and β-Klotho. In various embodiments the metabolic disease or disorder is diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

9. 发明公开

EP2613146A4 METHOD FOR ASSAYING FIBROBLAST GROWTH FACTOR-23 AND ASSAY REAGENT 有权
标题翻译： VERFAHREN ZUR BESTIMMUNG DES FIBROBLASTEN-WACHSTUMSFAKTORS 23 UND ASSAYREAGENSDAFÜR
公开(公告)号：EP2613146A4
公开(公告)日：2014-03-19
申请号：EP11821852
申请日：2011-08-31
申请人： KYOWA MEDEX CO LTD
发明人： UZAWA KOJI , SUZUKI EMIKO , IKEDA KAZUYUKI , MORITA KAZUKI
IPC分类号： G01N33/543 , G01N33/74
CPC分类号： G01N33/74 , G01N33/54326 , G01N2333/50

10. 发明公开

EP2695950A1 Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor 审中-公开
标题翻译： Markerfürdie Empfindlichkeit auf einen Hemmer des Fibroblastenwachstumsrezeptors
公开(公告)号：EP2695950A1
公开(公告)日：2014-02-12
申请号：EP12180179.9
申请日：2012-08-10
申请人： Blackfield AG
发明人： Thomas, Roman , Malchers, Florian
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/57423 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/6863 , G01N2333/50 , G01N2333/71
摘要： The present invention relates to a method for predicting the responsiveness of a mammalian tumor cell or cancer cell to an inhibitor of a fibroblast growth factor receptor (FGFR). Also a method for predicting the responsiveness of an individual to an inhibitor of a fibroblast growth factor receptor (FGFR) is provided. These methods involve the evaluation of the status of FGFR and the status of c-myc, whereby said status of FGFR and of c-myc is indicative for the responsiveness to the inhibitor. The status of FGFR may be its amplifcation status or its expression level and the status of c-myc may be its expression level, like an intermediate or high expression level of c-myc. Furthermore, a kit useful for carrying out the methods described herein as well as an oligo- or polynucleotide and/or antibodies capable of detecting the expression level or gene amplification status of FGFR or the expression level of c-myc for predicting the responsiveness to the inhibitor are provided.
摘要翻译：本发明涉及一种预测哺乳动物肿瘤细胞或癌细胞对成纤维细胞生长因子受体（FGFR）抑制剂的反应性的方法。还提供了预测个体对成纤维细胞生长因子受体（FGFR）的抑制剂的反应性的方法。这些方法包括评估FGFR的状态和c-myc的状态，由此所述FGFR和c-myc的状态指示对抑制剂的反应。 FGFR的状态可能是其扩增状态或其表达水平，c-myc的状态可能是其表达水平，如c-myc的中等或高表达水平。此外，可用于实施本文所述方法的试剂盒以及能够检测FGFR的表达水平或基因扩增状态的寡核苷酸和/或抗体或c-myc的表达水平用于预测对提供抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式